On October 6, Repligen fell 6.33% in regular trading, trading at $177.505/share, with turnover of $124 million.

The decline followed the company's formal announcement of completing its acquisition of BioLife Solutions, a deal valued at approximately $1.5 billion in cash and stock. Under the terms, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, implying a per-share valuation of about $31 for BioLife, a premium of roughly 6.2% to its prior close.

The acquisition provides Repligen with BioLife's cell preservation technology, cell processing tools, and higher-margin consumables business, aimed at strengthening its position in the cell therapy market. Separately, S&P Dow Jones Indices announced that Freshworks will replace BioLife Solutions in the S&P SmallCap 600 effective October 8, following the completion of the transaction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)